Clinical Trial Update: A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial studying recombinant vaccinia virus before sorafenib for unresectable primary hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Recombinant Vaccinia Virus
• Sorafenib (Sorafenib)

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED